DK1240901T3 - Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation - Google Patents

Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation

Info

Publication number
DK1240901T3
DK1240901T3 DK00987688T DK00987688T DK1240901T3 DK 1240901 T3 DK1240901 T3 DK 1240901T3 DK 00987688 T DK00987688 T DK 00987688T DK 00987688 T DK00987688 T DK 00987688T DK 1240901 T3 DK1240901 T3 DK 1240901T3
Authority
DK
Denmark
Prior art keywords
blood coagulation
prevention
treatment
disorders
pharmaceutical composition
Prior art date
Application number
DK00987688T
Other languages
English (en)
Inventor
Tatsuya Araki
Yasushi Nakatomi
Kazuhiko Tomokiyo
Kaori Teshima
Tomoko Watanabe
Tomohiro Nakagaki
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of DK1240901T3 publication Critical patent/DK1240901T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00987688T 1999-12-24 2000-12-21 Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation DK1240901T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP36812299A JP4676585B2 (ja) 1999-12-24 1999-12-24 血液凝固異常に基づく疾患の治療・予防用医薬組成物
PCT/JP2000/009102 WO2001047548A1 (fr) 1999-12-24 2000-12-21 Compositions medicinales de traitement et de prevention de maladies basees sur une coagulation sanguine anormale

Publications (1)

Publication Number Publication Date
DK1240901T3 true DK1240901T3 (da) 2008-11-10

Family

ID=18491024

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00987688T DK1240901T3 (da) 1999-12-24 2000-12-21 Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation

Country Status (9)

Country Link
US (1) US6881721B2 (da)
EP (1) EP1240901B1 (da)
JP (1) JP4676585B2 (da)
CN (1) CN1222311C (da)
AT (1) ATE407692T1 (da)
DE (1) DE60040236D1 (da)
DK (1) DK1240901T3 (da)
ES (1) ES2312374T3 (da)
WO (1) WO2001047548A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101067400B1 (ko) * 2001-07-10 2011-09-27 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 약제학적으로 안정한 지혈용 조성물
JP2007055899A (ja) * 2003-10-27 2007-03-08 Chemo Sero Therapeut Res Inst 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2008023052A1 (en) * 2006-08-24 2008-02-28 Novo Nordisk Health Care Ag Combination of a fvii and a thrombin-activable factor x
EP2201953A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
DK2555704T3 (da) 2010-04-08 2019-08-05 Hemosonics Llc Visning af hæmostatiske parametre

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287180A (en) * 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
US4286056A (en) * 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
DE3165600D1 (en) 1980-01-28 1984-09-27 Baxter Travenol Lab Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4663164A (en) * 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
US4459288A (en) * 1981-05-11 1984-07-10 Baxter Travenol Laboratories, Inc. Therapeutic blood clotting factor compositions and their use
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
WO1995029259A1 (en) * 1994-04-22 1995-11-02 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Method and means for detecting and treating disorders in the blood coagulation cascade
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
JPH1059866A (ja) 1996-08-19 1998-03-03 Chemo Sero Therapeut Res Inst 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
JP4046377B2 (ja) 1996-08-19 2008-02-13 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子の活性化方法及び該方法に基づく活性化血液凝固第ｖｉｉ因子の製造方法

Also Published As

Publication number Publication date
EP1240901B1 (en) 2008-09-10
JP4676585B2 (ja) 2011-04-27
CN1222311C (zh) 2005-10-12
DE60040236D1 (de) 2008-10-23
US20030060411A1 (en) 2003-03-27
EP1240901A4 (en) 2005-01-12
JP2001181204A (ja) 2001-07-03
WO2001047548A1 (fr) 2001-07-05
US6881721B2 (en) 2005-04-19
ATE407692T1 (de) 2008-09-15
CN1434720A (zh) 2003-08-06
EP1240901A1 (en) 2002-09-18
ES2312374T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
Honickel et al. Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
MY125150A (en) Factor vlla inhibitors
CA2931174A1 (en) No-emitting medical dressing comprising an no-generating module and a radiation-emitting module
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
Liu et al. Tranexamic acid reduces occult blood loss, blood transfusion, and improves recovery of knee function after total knee arthroplasty: a comparative study
Rodgers Prothrombin complex concentrates in emergency bleeding disorders
Longhurst Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?
WO2007106893A3 (en) Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
Pachauri et al. The effect of tranexamic acid on hemoglobin levels during total knee arthroplasty
Avanoglu et al. Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis
Kapadia et al. Reducing perioperative blood loss with antifibrinolytics and antifibrinolytic-like agents for patients undergoing total hip and total knee arthroplasty
WO2002034201A3 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
DE60043346D1 (de) Methoden zur hemmung der aktivität der osteoklasten
Rai et al. Efficacy of feracrylum as topical hemostatic agent in therapeutically anticoagulated patients undergoing dental extraction: A comparative study
DE69934689D1 (de) Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
EP1240901A4 (en) MEDICINAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF DISEASES BASED ON ABNORMAL BLOOD COAGULATION
Bernet et al. Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin‐treated patients
Petratos et al. Transforming growth factor‐β2 (TGF‐β2) reverses the inhibitory effects of fibrin sealant on cutaneous wound repair in the pig
FR2773712B1 (fr) Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
WO2001011038A3 (en) Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen